XBRANE BIOPHARMA AB: OXFORD NANOPORE TECHNOLOGIES LICENSES XBRANE BIOPHARMA’S PROTEIN PRODUCTION TECHNOLOGY

Oxford Nanopore Technologies licenses Xbrane Biopharma’s protein production technology

Xbrane Biopharma AB has entered into a licence agreement with Oxford Nanopore Technologies regarding Xbrane’s technology for the production of proteins used within Oxford Nanopore Technologies DNA sequencing technology. The compensation for the agreement is an un-disclosed annual license fee.

“We are very pleased to have reached an agreement with Oxford Nanopore Technologies, one of the worlds leading companies within DNA sequencing technology. Xbrane’s superior technology will be used for producing important proteins to be used for enabling the DNA sequencing in Oxford Nanopore Technologies’ DNA sequencing technology. This agreement demonstrates the versatility of Xbrane’s technology and the opportunities that exists within other types of industrial applications”, says Martin Åmark, CEO of Xbrane Biopharma AB.

“We are delighted to be collaborating with Xbrane on this technology component,” said Dr G

< | >